IL98156A - Pharmaceutical preparations containing magnesium-fidoxal-'5-phosphate-glutamine - Google Patents

Pharmaceutical preparations containing magnesium-fidoxal-'5-phosphate-glutamine

Info

Publication number
IL98156A
IL98156A IL9815691A IL9815691A IL98156A IL 98156 A IL98156 A IL 98156A IL 9815691 A IL9815691 A IL 9815691A IL 9815691 A IL9815691 A IL 9815691A IL 98156 A IL98156 A IL 98156A
Authority
IL
Israel
Prior art keywords
phosphate
pyridoxal
glutaminate
ldl
composition according
Prior art date
Application number
IL9815691A
Other languages
English (en)
Hebrew (he)
Other versions
IL98156A0 (en
Original Assignee
Steigerwald Arzneimittelwerk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steigerwald Arzneimittelwerk filed Critical Steigerwald Arzneimittelwerk
Publication of IL98156A0 publication Critical patent/IL98156A0/xx
Publication of IL98156A publication Critical patent/IL98156A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL9815691A 1990-05-25 1991-05-16 Pharmaceutical preparations containing magnesium-fidoxal-'5-phosphate-glutamine IL98156A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4016963A DE4016963A1 (de) 1990-05-25 1990-05-25 Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben

Publications (2)

Publication Number Publication Date
IL98156A0 IL98156A0 (en) 1992-06-21
IL98156A true IL98156A (en) 1996-06-18

Family

ID=6407228

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9815691A IL98156A (en) 1990-05-25 1991-05-16 Pharmaceutical preparations containing magnesium-fidoxal-'5-phosphate-glutamine

Country Status (28)

Country Link
US (1) US5372999A (ko)
EP (1) EP0458287B1 (ko)
JP (1) JPH07119174B2 (ko)
KR (1) KR970005180B1 (ko)
CN (1) CN1050750C (ko)
AT (1) ATE142884T1 (ko)
AU (1) AU651108B2 (ko)
CA (1) CA2043228C (ko)
CZ (1) CZ280683B6 (ko)
DE (2) DE4016963A1 (ko)
DK (1) DK0458287T3 (ko)
EG (1) EG19730A (ko)
ES (1) ES2091262T3 (ko)
GR (1) GR3021077T3 (ko)
HR (1) HRP931445B1 (ko)
HU (1) HU219223B (ko)
IE (1) IE76728B1 (ko)
IL (1) IL98156A (ko)
IN (1) IN173057B (ko)
LT (1) LT3335B (ko)
LV (1) LV10046B (ko)
MD (1) MD306C2 (ko)
MX (1) MX171883B (ko)
RU (1) RU2041713C1 (ko)
SI (1) SI9110925A (ko)
SK (1) SK278896B6 (ko)
UA (1) UA26973A1 (ko)
ZA (1) ZA913692B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19527820A1 (de) * 1995-07-28 1997-01-30 Leniger Follert Elfriede Prof Arzneimittel zur Behandlung von Ulcera, insbesondere bei arteriellen und venösen Durchblutungsstörungen der Extremitäten, bei chronisch venöser Insuffizienz und Lymphödem
DE19532625C2 (de) * 1995-09-04 2000-04-20 Steigerwald Arzneimittelwerk Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
DE60023125T2 (de) 1999-03-08 2006-06-22 University Of Manitoba, Winnipeg Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
EP1872797A3 (en) * 1999-08-24 2008-04-02 Medicure International Inc. Treatment of cardiovascular and related pathologies
DE60110054T2 (de) 2000-02-29 2006-03-09 Medicure International Inc. Cardioprotektive phosphonate
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
AU784840B2 (en) 2000-03-28 2006-07-06 Medicure International Inc. Treatment of cerebrovascular disease
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
WO2002004421A2 (en) 2000-07-07 2002-01-17 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
CA2585165A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
AU2008224883A1 (en) 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilization of a cell and/or macromolecule
RU2484843C1 (ru) * 2012-04-03 2013-06-20 Алексей Кириллович Пехтерев Лекарственный сбор растений для лечения сердечно-сосудистых заболеваний

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246172C (ko)
DE2461742C2 (de) * 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker

Also Published As

Publication number Publication date
CN1050750C (zh) 2000-03-29
HRP931445B1 (en) 2000-04-30
IN173057B (ko) 1994-02-05
LTIP580A (en) 1994-12-27
ATE142884T1 (de) 1996-10-15
DK0458287T3 (da) 1996-10-07
DE4016963C2 (ko) 1992-04-30
CA2043228C (en) 1998-07-14
IE76728B1 (en) 1997-11-05
EG19730A (en) 1996-01-31
HUT58204A (en) 1992-02-28
CS156391A3 (en) 1992-02-19
RU2041713C1 (ru) 1995-08-20
JPH04235130A (ja) 1992-08-24
CN1057391A (zh) 1992-01-01
MD306B1 (ro) 1995-10-31
UA26973A1 (uk) 2000-02-28
LT3335B (en) 1995-07-25
HRP931445A2 (en) 1996-02-29
LV10046A (lv) 1994-05-10
AU651108B2 (en) 1994-07-14
AU7730191A (en) 1991-11-28
HU911756D0 (en) 1991-12-30
CZ280683B6 (cs) 1996-04-17
LV10046B (en) 1995-02-20
KR910019616A (ko) 1991-12-19
GR3021077T3 (en) 1996-12-31
DE69122170T2 (de) 1997-02-20
EP0458287A2 (en) 1991-11-27
KR970005180B1 (ko) 1997-04-14
EP0458287B1 (en) 1996-09-18
ES2091262T3 (es) 1996-11-01
DE4016963A1 (de) 1991-11-28
MX171883B (es) 1993-11-22
IL98156A0 (en) 1992-06-21
JPH07119174B2 (ja) 1995-12-20
CA2043228A1 (en) 1991-11-26
IE911783A1 (en) 1991-12-04
MD306C2 (ro) 1996-02-29
HU219223B (en) 2001-03-28
SI9110925A (sl) 1998-06-30
US5372999A (en) 1994-12-13
SK278896B6 (sk) 1998-04-08
ZA913692B (en) 1992-02-26
DE69122170D1 (de) 1996-10-24
EP0458287A3 (en) 1992-04-08

Similar Documents

Publication Publication Date Title
US5372999A (en) Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which result from vascular lesions
Nozaki et al. Postheparin lipolytic activity and plasma lipoprotein response to ω-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia
Garg et al. Management of dyslipidemia in NIDDM
TW201900160A (zh) 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
Neuzil et al. The role of vitamin E in atherogenesis: linking the chemical, biological and clinical aspects of the disease
JP2018184463A (ja) スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
Colwell Aspirin therapy in diabetes
JP2009544590A (ja) ビタミンｋ２を含む医薬及び栄養補助製品
CA3147657A1 (en) Ethyl eicosapentaenoate for maintaining ldl control
JP2013516457A (ja) Ｖｂ−２０１を用いた併用治療法
KR20070108383A (ko) 지질 저하성 화합물
MX2011005077A (es) Un metodo para reducir el complejo de lipoproteina-beta-2-glicopro teina 1 de baja densidad oxidado circulante para el tratamiento de ateroesclerosis.
Brattström et al. Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate
Rubenfire et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia
Ditschuneit et al. Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridaemia: effects of gemfibrozil
Chin-Dusting et al. Lipids and atherosclerosis: clinical management of hypercholesterolaemia
BARKER Occlusive arterial disease of the lower extremities associated with lipemia and xanthoma tuberosum
Haines et al. Assessment and management of lipid disorders in men
Beest Overanticoagulation on coumarin anticoagulants
Palareti et al. Anticoagulation: Heparins and Vitamin K Antagonists
Blum Combination Drug Therapy in a Case of Severe Hypercholesterolemia
RU2408382C2 (ru) Применение биологически активной добавки к пище "провитам" в качестве ингибитора перекисного окисления липидов
Basit et al. Frequency of statin use in type 2 diabetics having macrovascular disease-at a Tertiary Care Hospital of Karachi
Carr A Young Man with Abdominal Pain and Very High Triglycerides: The Chylomicronemia Syndrome
Sulaiman et al. Does Vitamin E Improve Hyperlipidemia in Patients with Crdiovascular Disease?

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed